Kohji Takemura, MD· @KohjiToncol · X·· 4 天前评分45
正文 · 原文
JNJ-6143: A first-in-class RIPTAC with a novel mechanism of action targeting AR and BRD4.
Promising phase 1 efficacy and safety in heavily pretreated mCRPC.
Potential activity even in patients with high-risk molecular features. Looking forward to further development!
#ESMO26
15 浏览 · 0 赞 · 0 转发 · 0 回复
来源：Kohji Takemura, MD · x.com